GENB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026
Revenue
4.2M
-33.2%
6.3M
-12.6%
7.2M
Cost of Revenue
0
0
0
Gross Profit
4.2M
-33.2%
6.3M
-12.6%
7.2M
Operating Expenses
95.7M
+22.8%
77.9M
+9.2%
71.3M
R&D
82.3M
+27.9%
64.3M
+11.3%
57.8M
SG&A
13.5M
-0.9%
13.6M
+0.5%
13.5M
Operating Income
-91507000
-27.8%
-71614000
-11.7%
-64112000
EBITDA
-87813000
-28.4%
-68390000
-12.4%
-60839000
Net Income
-87657000
-30.3%
-67255000
-9.0%
-61714000
EPS (Basic)
$-0.68
-30.8%
$-0.52
+51.4%
$-1.07
EPS (Diluted)
$-0.68
-30.8%
$-0.52
+51.4%
$-1.07
Shares (Diluted)
128.5M
+0.2%
128.2M
+97.7%
64.9M
Generate Biomedicines (GENB) — Financials